Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 20% ± 3% | |
astrocyte | 3 studies | 20% ± 3% |
Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 3 studies | 20% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 5320.53 | 1445 / 1445 | 99% | 15.03 | 181 / 183 |
lung | 100% | 5527.93 | 577 / 578 | 99% | 13.10 | 1139 / 1155 |
stomach | 100% | 5537.39 | 359 / 359 | 98% | 12.25 | 281 / 286 |
intestine | 100% | 6699.41 | 966 / 966 | 98% | 12.02 | 515 / 527 |
skin | 100% | 4335.90 | 1803 / 1809 | 97% | 13.58 | 459 / 472 |
thymus | 100% | 15414.14 | 653 / 653 | 97% | 17.42 | 585 / 605 |
ovary | 100% | 10773.72 | 180 / 180 | 96% | 14.83 | 414 / 430 |
kidney | 100% | 6480.09 | 89 / 89 | 96% | 16.65 | 867 / 901 |
pancreas | 100% | 5496.43 | 328 / 328 | 96% | 14.42 | 171 / 178 |
bladder | 100% | 6301.76 | 21 / 21 | 96% | 13.23 | 483 / 504 |
breast | 100% | 6679.87 | 459 / 459 | 96% | 12.87 | 1068 / 1118 |
prostate | 100% | 7540.42 | 245 / 245 | 94% | 11.43 | 474 / 502 |
adrenal gland | 100% | 6820.04 | 257 / 258 | 93% | 12.16 | 215 / 230 |
brain | 94% | 4352.77 | 2474 / 2642 | 99% | 19.07 | 698 / 705 |
uterus | 100% | 7975.58 | 170 / 170 | 92% | 12.02 | 423 / 459 |
liver | 100% | 7351.99 | 225 / 226 | 87% | 9.57 | 352 / 406 |
spleen | 100% | 8712.02 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 7.68 | 1 / 1 |
adipose | 100% | 5382.26 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 99% | 4089.76 | 1328 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 4013.28 | 843 / 861 | 0% | 0 | 0 / 0 |
muscle | 98% | 3362.34 | 784 / 803 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 9.77 | 76 / 80 |
tonsil | 0% | 0 | 0 / 0 | 93% | 11.74 | 42 / 45 |
lymph node | 0% | 0 | 0 / 0 | 76% | 10.51 | 22 / 29 |
peripheral blood | 49% | 1771.95 | 456 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000289 | Biological process | nuclear-transcribed mRNA poly(A) tail shortening |
GO_0010606 | Biological process | positive regulation of cytoplasmic mRNA processing body assembly |
GO_0006397 | Biological process | mRNA processing |
GO_0000932 | Cellular component | P-body |
GO_0031251 | Cellular component | PAN complex |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0000175 | Molecular function | 3'-5'-RNA exonuclease activity |
GO_0004535 | Molecular function | poly(A)-specific ribonuclease activity |
GO_0003676 | Molecular function | nucleic acid binding |
GO_0005515 | Molecular function | protein binding |
GO_0004843 | Molecular function | cysteine-type deubiquitinase activity |
GO_0046872 | Molecular function | metal ion binding |
Gene name | PAN2 |
Protein name | PAN2-PAN3 deadenylation complex catalytic subunit PAN2 (EC 3.1.13.4) (Inactive ubiquitin carboxyl-terminal hydrolase 52) (PAB1P-dependent poly(A)-specific ribonuclease) (Poly(A)-nuclease deadenylation complex subunit 2) (PAN deadenylation complex subunit 2) Poly(A) specific ribonuclease subunit PAN2 |
Synonyms | USP52 KIAA0710 |
Description | FUNCTION: Catalytic subunit of the poly(A)-nuclease (PAN) deadenylation complex, one of two cytoplasmic mRNA deadenylases involved in general and miRNA-mediated mRNA turnover. PAN specifically shortens poly(A) tails of RNA and the activity is stimulated by poly(A)-binding protein (PABP). PAN deadenylation is followed by rapid degradation of the shortened mRNA tails by the CCR4-NOT complex. Deadenylated mRNAs are then degraded by two alternative mechanisms, namely exosome-mediated 3'-5' exonucleolytic degradation, or deadenylation-dependent mRNA decaping and subsequent 5'-3' exonucleolytic degradation by XRN1. Also acts as an important regulator of the HIF1A-mediated hypoxic response. Required for HIF1A mRNA stability independent of poly(A) tail length regulation. . |
Accessions | Q504Q3 ENST00000548043.5 [Q504Q3-1] ENST00000425394.7 [Q504Q3-1] F8VXK8 ENST00000547572.1 ENST00000440411.8 [Q504Q3-2] ENST00000610546.4 [Q504Q3-1] ENST00000257931.9 [Q504Q3-3] |